The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had presented at the "Asia-Pacific (APAC)" track of the J.P.

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Reminders of the killing of UnitedHealthcare CEO Brian Thompson were everywhere at this year's J.P. Morgan conference.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

The current head of the Center for Medicare has advice for her successor: "Engaging everyone in the ecosystem" is the ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Healthcare & Pharmaceuticalscategory Novartis wins temporary pause to Entresto generic launch in US 2:11 AM UTC Legalcategory Gilead Sciences, US government settle patent case over HIV prevention ...

These large, stable leaders all have $40 billion-plus businesses and dividends above 2%.